Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Long-Term Deferred Tax (2018 - 2019)

Insight Molecular Diagnostics' Long-Term Deferred Tax history spans 1 years, with the latest figure at $35.6 million for Q4 2019.

On a quarterly basis, Long-Term Deferred Tax changed N/A to $35.6 million in Q4 2019 year-over-year; TTM through Dec 2019 was $35.6 million, a N/A change, with the full-year FY2019 number at $35.6 million, changed N/A from a year prior.
Long-Term Deferred Tax hit $35.6 million in Q4 2019 for Insight Molecular Diagnostics.
Over the last five years, Long-Term Deferred Tax for IMDX hit a ceiling of $35.6 million in Q4 2019 and a floor of $35.6 million in Q4 2019.